Full Press Release Details
Semler Reports Record Second Quarter
and First Half 2019 Financial Results
2019 Q2 HIGHLIGHTS compared to the corresponding period of
San Jose, Cal. - July 26, 2019 - Semler Scientific,
Inc. (OTCQB: SMLR), an emerging growth company that provides technology solutions to improve
the clinical effectiveness and efficiency of healthcare providers, today reported financial results for the three and six
months ended June 30, 2019.
"Our vascular testing product and data services are intended
to help our customers solve problems encountered by underserved communities, diabetic populations, women and the elderly, among
others," said Doug Murphy-Chutorian, M.D., chief executive officer ("CEO") of Semler Scientific. "We believe
that early identification of chronic disease and preventive healthcare delivers clinical benefits and cost-effective value to patients
at risk, especially those people who are neglected or unrecognized by current practices."
For the quarter ended June 30, 2019, compared to the corresponding
period of 2018, Semler Scientific reported:
For the six months ended June 30, 2019, compared to the corresponding
period of 2018, Semler Scientific reported:
SECOND QUARTER 2019 MAJOR ACCOMPLISHMENTS
Among the achievements during the second quarter of 2019 were:
"We are pleased with the continued growth of our current
book of business and with the inroads we are making with new customers. We believe we are well positioned to handle increased order
sizes to satisfy future demand for our QuantaFlo product. Our two largest customers comprise 51% and 15% of quarterly revenues.
License revenues were approximately $5.4 million, variable priced revenues were approximately $2.3 million and equipment sales
were $306,000," said Dr. Murphy-Chutorian.
In 2019, Semler Scientific expects continued profitability and
generation of cash from operating activities, as well as increased spending to support anticipated growth in its business. It is
the company's intent to grow revenues at a faster rate than expenses and to remain profitable.
"The stakeholders in the delivery of and payment for medical
care are actively trying to improve their service and economics to the community," continued Dr. Murphy-Chutorian. "Their
objectives to encourage healthier lifestyles, ameliorate risk factors, diminish morbidity and decrease mortality, are synergistic
with the use our products as an aid to direct appropriate preventative care measures to their patients."
Notice of Conference Call
Semler Scientific will not host a conference call to discuss
results of the second quarter and first half of 2019 as its CEO continues to make strong progress recovering from a mild stroke.
Semler Scientific anticipates that it will host a conference call to discuss the third quarter and first nine months of 2019, with
additional executives joining the CEO on such call.
About Semler Scientific, Inc.:
Semler Scientific, Inc. is an
emerging growth company that provides technology solutions to improve the clinical effectiveness and efficiency of healthcare
providers. Semler Scientific's mission is to develop, manufacture and market innovative proprietary products and services
that assist its customers in evaluating and treating chronic diseases. Semler Scientific commercially launched its first
patented and U.S. Food and Drug Administration, or FDA, cleared product in 2011,and received FDA 510(k) clearance for QuantaFlo ,
the next generation version of this product in 2015. QuantaFlo is a rapid point-of-care test that measures arterial blood
flow in the extremities to aid in the diagnosis of peripheral arterial disease. QuantaFlo is used by Semler Scientific's
customers to more comprehensively evaluate their patients for risk of heart attacks and strokes. Semler Scientific believes it
is positioned to provide valuable information to its insurance company and physician customers, which in turn permits them to
better guide patient care. Additional information about Semler Scientific can be found at semlerscientific.com.
Forward-Looking Statements
This press release contains "forward-looking" statements.
Such statements can be identified by, among other things, the use of forward-looking language such as the words "may,"
"will," "intend," "expect," "anticipate," "estimate," "project,"
"would," "could" or words with similar meaning or the negatives of these terms or by the discussion of
strategy or intentions. The forward-looking statements in this release include statements regarding continued profitability and
cash generation from operations, the ability to grow revenues faster than expenses and remain profitable, as well as increased
spending to support anticipated growth in the business. Such forward-looking statements are subject to a number of risks and uncertainties
that could cause Semler Scientific's actual results to differ materially from those discussed here, such as whether or not
insurance plans and other customers will continue to license its cardiovascular testing products, and its ability to continue to
control expenses, along with those statements detailed in Semler Scientific's SEC filings. These forward-looking statements
involve assumptions, estimates, and uncertainties that reflect current internal projections, expectations or beliefs. There can
be no assurance that such statements will prove to be accurate, and actual results and future events could differ materially from
those anticipated in such statements. All forward-looking statements contained in this press release are qualified in their entirety
by these cautionary statements and the risk factors described above. Furthermore, all such statements are made as of the date of
this release and Semler Scientific assumes no obligation to update or revise these statements unless otherwise required by law.
S.A. Noonan Communications
SOURCE: Semler Scientific, Inc.
Semler Scientific, Inc.
Condensed Statements of Income
(In thousands of U.S. Dollars, except for
share and per share data)
| For the three months ended June 30, | For the six months ended June 30, | |||||||||||||||
| (Unaudited) | (Unaudited) | |||||||||||||||
| 2019 | 2018 | 2019 | 2018 | |||||||||||||
| Revenues | $ | 7,953 | $ | 5,484 | $ | 14,714 | $ | 9,947 | ||||||||
| Operating expenses: | ||||||||||||||||
| Cost of revenues | 885 | 680 | 1,781 | 1,384 | ||||||||||||
| Engineering and product development | 591 | 489 | 1,160 | 856 | ||||||||||||
| Sales and marketing | 2,212 | 1,779 | 4,281 | 3,484 | ||||||||||||
| General and administrative | 1,570 | 1,001 | 2,943 | 1,875 | ||||||||||||
| Total operating expenses | 5,258 | 3,949 | 10,165 | 7,599 | ||||||||||||
| Income from operations | 2,695 | 1,535 | 4,549 | 2,348 | ||||||||||||
| Interest income (expense) | 1 | (9 | ) | 2 | (56 | ) | ||||||||||
| Interest expense -- related parties | - | (72 | ) | - | (131 | ) | ||||||||||
| Other expense | - | (1 | ) | (2 | ) | (2 | ) | |||||||||
| Other income (expense) | 1 | (82 | ) | - | (189 | ) | ||||||||||
| Pre-tax net income | $ | 2,696 | $ | 1,453 | $ | 4,549 | $ | 2,159 | ||||||||
| Provision for taxes | $ | 77 | - | 77 | - | |||||||||||
| Net income | $ | 2,619 | 1,453 | 4,472 | 2,159 | |||||||||||
| Net income per share: | ||||||||||||||||
| Basic | $ | 0.41 | 0.24 | $ | 0.70 | 0.36 | ||||||||||
| Diluted | $ | 0.32 | $ | 0.19 | $ | 0.55 | $ | 0.29 | ||||||||
| Weighted average number of shares used in computing income per share: | ||||||||||||||||
| Basic | 6,411,606 | 5,982,711 | 6,368,905 | 5,953,818 | ||||||||||||
| Diluted | 8,086,140 | 7,534,846 | 8,128,241 | 7,403,498 |
Semler Scientific, Inc.
Condensed Balance Sheets
(In thousands of U.S. Dollars)
| At June 30, | At December 31, | |||||||
| 2019 | 2018 | |||||||
| (Unaudited) | ||||||||
| Cash | $ | 4,182 | $ | 3,284 | ||||
| Other current assets | 3,722 | 2,954 | ||||||
| Noncurrent assets | 1,920 | 1,481 | ||||||
| Total assets | 9,824 | 7,719 | ||||||
| Current liabilities | 3,594 | 3,512 | ||||||
| Noncurrent liabilities | 9 | 11 | ||||||
| Stockholders' equity | 6,221 | 4,196 | ||||||
| Total liabilities and stockholders' equity | $ | 9,824 | $ | 7,719 |